In a report published Tuesday morning, Barclays analyst Ying Huang initiated coverage on GlycoMimetics Inc GLYC. Barclays kick off the GLYC coverage with an Overweight rating and price target of $15.
The report highlights the company's progress "Currently
GlycoMimetics has one partnered asset (GMI-1070) set to begin Phase III testing in sickle cell disease (SCD) by mid-year and a proprietary compound (GMI-1271) it
hopes to enter clinical testing soon. These agents block a class of molecules on epithelial cells termed selectins, which are involved in cell mobility and adhesion.
GlycoMimetics also has an early-stage pipeline of several pre-clinical compounds which it hopes to develop across a variety of diseases."
GLYC closed Monday at $10.01 and opened Tuesday morning at $10.22.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in